Eye care services provider Dr Agarwal's Health Care, which is set to launch its ₹3,027 crore IPO this week, plan to merge its listed subsidiary, Dr Agarwal Eye Hospital, with the parent company post listing. In an interaction with Fortune India, Dr. Adil Agarwal, a Whole-time Director and the CEO of the company, shared his views on the IPO decision, how fundraising will help in debt reduction, and explained how India’s eye care market faces a huge challenge of bridging the deficit of optometrists.
Backed by private equity firms TPG and Temase, Dr. Agarwal's Health Care looks to raise ₹3,027 crore at a market value of ₹12,698 crore at the upper end of the price band of ₹382 to ₹402 per equity share. The three-day IPO will open for subscription on January 29, 2025, while the tentative date for listing of the stock on the BSE and NSE is February 5, 2025.
Fortune India is now on WhatsApp! Get the latest updates from the world of business and economy delivered straight to your phone. Subscribe now.